본문바로가기
Q
U
I
C
K

Business

SK bioscience’s effort reaches beyond development and manufacture of premium vaccines
and extends to working with domestic and overseas partners to create a healthy future for mankind.

In-house Products

SK bioscience develops vaccines with its innovative technology and produces them under a strict quality control system.
WHO PQ prequalified typhoid conjugate vaccine

SKY Typhoid Multi Inj.

(Thyphoid purified Vi Polysaccharide Conjugated to Diphtheria toxoid vaccine)

SKY Typhoid Multi Inj. image
The first Korean-developed COVID-19 Vaccine

SKYCovione™

(SARS-CoV-2, Surface Antigen (Recombinant DNA))

SKYCovione™ image
the world’s first-developed quadrivalent cell culture-based influenza vaccine

SKYCellflu® Quadrivalent Prefilled Syringe

(cell culture-based influenza vaccine)

SKYCellflu® Quadrivalent Prefilled Syringe image
The world’s second developed shingles vaccine

SKYZoster®

(Live Attenuated Vaccine)

SKYZoster® image
The WHO PQ certification obtained varicella vaccine

SKYVaricella®

(Live Attenuated Vaccine)

SKYVaricella® image
Learn more about SK bioscience’s pipeline​